Corilagin alleviates podocyte injury in diabetic nephropathy by regulating autophagy the SIRT1-AMPK pathway.

Background: Diabetic nephropathy (DN) is the most frequent chronic microvascular consequence of diabetes, and podocyte injury and malfunction are closely related to the development of DN. Studies have shown that corilagin (Cor) has hepatoprotective, anti-inflammatory, antibacterial, antioxidant, anti-hypertensive, anti-diabetic, and anti-tumor activities.

Aim: To explore the protective effect of Cor against podocyte injury in DN mice and the underlying mechanisms.